CEO, Endogena Therapeutics Inc.
Matthias Steger is CEO of Endogena Therapeutics Inc., a new biotech company focusing on the discovery and development of endogenous regenerative medicines. Prior to Endogena, he worked 18 years in the field of drug discovery, most recently as Global Head of Research & Technology Partnering, at Roche, setting up and managing > 50 collaborations and acquisitions for novel drug modalities, new drug discovery technologies, as well as enabling technologies, such as translational models, biomarkers, and drug delivery/formulation. Matthias has also lead and implemented various corporate strategies exploring novel drug discovery approaches, and as such has initiated and built up Roche’s stem cell research.
In addition, Matthias worked as an independent consultant for various biotech companies, academic institutes and venture capital firms, exploring novel drug discovery – and partnering / investment strategies. He also has prior entrepreneurial experience by building up a pioneering orphan GPCR drug discovery company, which lead to a successful acquisition. Matthias started his career in research, as a medicinal chemist at Roche, exploring novel platforms and drug design approaches, as well as traditional drug discovery programs. He also gained a financial perspective of the industry as an investment banking analyst at Kepler Equities.
He served as an executive board member of the Alliance for Regenerative Medicine (ARM), as well as the chair of the industry committee of the International Society of Stem Cell Research (ISSCR). Matthias has a Diploma in Organic Chemistry (University of Zürich, Switzerland), and a PhD in Medicinal Chemistry from the University of Sussex, UK, as well as an MBA from HSG (St. Gallen, Switzerland).